Mars landing

NASA and Johnson Space Center celebrate unprecedented Mars Perseverance landing

Perseverance has landed on Mars. Illustration courtesy of NASA

While Houston is in the depths of a historic freeze, some spacey locals are celebrating a major cosmic milestone. NASA — and Johnson Space Center, locally — are toasting the landing of Perseverance, the amiable roving vehicle, on Mars.

The reliable rover, nicknamed "Percy," touched down on the rocky Red Planet at approximately 2:55 pm Houston time on Thursday, February 18, to cheers at JSC and at NASA's Jet Propulsion Laboratory in Southern California, which is spearheading the mission.

In a harrowing descent, described by NASA tech crews as "seven minutes of terror," the rover plunged through the thin Martian atmosphere at more than 12,000 mph. A 70-foot parachute and powered descent slowed the rover to about 2 mph before a "sky crane maneuver," and soft landing at Mars' Jezero Crater.

Importantly, the intrepid Perseverance is carrying the Ingenuity Mars Helicopter – that will attempt the first powered, controlled flight on another planet. Aside from undertaking crucial experiments and sample collections, the first order of business is ensuring that Perseverance is "healthy," said NASA Perseverance staffer, Jessica Samuels, on NASA TV.

"If there's one thing we know, it's that landing on Mars is never easy," said NASA associate administrator for Communications Marc Etkind, in a statement. "But as NASA's fifth Mars rover, Perseverance has an extraordinary engineering pedigree and mission team. We are excited to invite the entire world to share this exciting event with us!"

Proud, starry-eyed Houstonians can watch the developments live on NASA TV online.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted